Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Monthly Archives: July 2016

June 2016 OncoPoll – Skin Cancers

MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the fourth and final report for our 2016 series covering new data presented in Chicago.

This OncoPoll™ focuses on melanoma, with a little merkel cell carcinoma included for good measure. As with the entire melanoma therapy area for the past few years, it focuses of the use of the checkpoint inhibitors and BRAF + MEK inhibitors for the treatment of BRAF V600E/K-mutant melanoma.

Our most recent research from a global panel of active melanoma treaters reveals:
• Melanoma treaters in all locations continue to see updates and expansions about the use of the checkpoint inhibitors as very important clinical developments. Focus now is beginning to change towards combinations and use as initial treatment lines
• Physicians also recognize the utility and importance of targeted therapy for BRAF-mutant melanoma, especially now that longer-term data is becoming available
• Even though combinations of BRAF + MEK inhibitors will remain the primary 1st line treatment choice for BRAF-mutant melanoma for more treaters than anything else, the use of checkpoint inhibitors in the front line will make strong inroads as the preferred option

Download your complimentary copy of our report MDoutlook June 2016 Oncopoll – Skin Cancers.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.

To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!

Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDoutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.

June 2016 OncoPoll – GU Cancers

MDoutlook presents the results from our innovative initiative of syndicated research gauging the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the third of four reports in our 2016 series covering clinical news presented in Chicago.

This OncoPoll™ focuses on non-prostate genitourinary cancers – both bladder and kidney cancers. It covers the expansion of the use of the checkpoint inhibitors into bladder cancer and renal cell carcinoma and the head-to-head comparison of cabozantinib vs. everolimus in the Meteor trial.

Our most recent research from a global panel of active genitourinary cancer treaters reveals:
• Oncologists see the use of the checkpoint inhibitors in bladder cancer as a very important clinical development, especially by those in the US. A slightly higher level of clinical importance to the checkpoint inhibitors are placed on their usage in 2nd+ lines of therapy, compared to the use of the 1st line
• The integration of the recently-approved atezolizumab into clinical practice has started off quickly, with 40% of US oncologists reporting their use of it in bladder cancer within the first month
• Oncologists are also enthusiastic about the use of nivolumab and cabozantinib as therapeutics for patients with RCC
• The interchangeability of checkpoint inhibitors is also explored in this report

Download your complimentary copy of our report MDoutlook June 2016 Oncopoll – GU Cancers.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.

To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!

Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDoutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.

June 2016 OncoPoll – Lung Cancers

MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the second of four reports in our 2016 series covering news presented in Chicago.

This OncoPoll™ focuses on lung cancers, both non-small cell (NSCLC) and small cell (SCLC). It covers 2 abstracts about ALK+ NSCLC and 1 abstract in recurrent SCLC. Our most recent research from 146 global oncologists who are actively managing patients with lung cancer uncovers that:

  • Data presented from the J-ALEX trial examining the use of alectinib in the 1st line setting for ALK+ NSCLC is globally reported as clinically meaningful
  • The excitement is tempered somewhat, as most have some concerns since the data was from a single country. This makes the results of the global ALEX trial that much more eagerly awaited
  • The use of brigatinib in the 2nd line setting for ALK+ NSCLC was also assigned a relatively high level of clinical importance. This rating implies that it will be readily integrated into practices once it becomes commercially available
  • Oncologists are enthusiastic about the strategy of dual checkpoint inhibition for recurrent SCLC. Impressive levels of growth for both nivolumab alone and in combination with ipilimumab are expected in the very near future. Nivolumab is expected to be used in a majority of US recurrent SCLC patients over the next year

Download your complimentary copy of our report MDoutlook June 2016 OncoPoll – Lung Cancers.

MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.

To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!

Submitted by Dr. Robert Stephan, Vice President, Research and Physician Society, and Jan Heybroek, President of MDoutlook. All Rights Reserved ©2016. All registered trademarks are the property of their respective owners.